192 related articles for article (PubMed ID: 36149968)
21. Population Cellular Kinetics of Lisocabtagene Maraleucel, an Autologous CD19-Directed Chimeric Antigen Receptor T-Cell Product, in Patients with Relapsed/Refractory Large B-Cell Lymphoma.
Ogasawara K; Dodds M; Mack T; Lymp J; Dell'Aringa J; Smith J
Clin Pharmacokinet; 2021 Dec; 60(12):1621-1633. PubMed ID: 34125421
[TBL] [Abstract][Full Text] [Related]
22. Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study.
Siddiqi T; Maloney DG; Kenderian SS; Brander DM; Dorritie K; Soumerai J; Riedell PA; Shah NN; Nath R; Fakhri B; Stephens DM; Ma S; Feldman T; Solomon SR; Schuster SJ; Perna SK; Tuazon SA; Ou SS; Papp E; Peiser L; Chen Y; Wierda WG
Lancet; 2023 Aug; 402(10402):641-654. PubMed ID: 37295445
[TBL] [Abstract][Full Text] [Related]
23. Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma.
Elsawy M; Chavez JC; Avivi I; Larouche JF; Wannesson L; Cwynarski K; Osman K; Davison K; Rudzki JD; Dahiya S; Dorritie K; Jaglowski S; Radford J; Morschhauser F; Cunningham D; Martin Garcia-Sancho A; Tzachanis D; Ulrickson ML; Karmali R; Kekre N; Thieblemont C; Enblad G; Dreger P; Malladi R; Joshi N; Wang WJ; Solem CT; Snider JT; Cheng P; To C; Kersten MJ
Blood; 2022 Nov; 140(21):2248-2260. PubMed ID: 35839452
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of second-line lisocabtagene maraleucel in relapsed or refractory diffuse large B-cell lymphoma.
Choe JH; Yu T; Abramson JS; Abou-El-Enein M
Blood Adv; 2024 Jan; 8(2):484-496. PubMed ID: 38153350
[TBL] [Abstract][Full Text] [Related]
25. Comparative efficacy of tisagenlecleucel and lisocabtagene maraleucel among adults with relapsed/refractory large B-cell lymphomas: an indirect treatment comparison.
Schuster SJ; Zhang J; Yang H; Agarwal A; Tang W; Martinez-Prieto M; Bollu V; Kuzan D; Maziarz RT; Kersten MJ
Leuk Lymphoma; 2022 Apr; 63(4):845-854. PubMed ID: 34978255
[TBL] [Abstract][Full Text] [Related]
26. Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma.
Westin JR; Locke FL; Dickinson M; Ghobadi A; Elsawy M; van Meerten T; Miklos DB; Ulrickson ML; Perales MA; Farooq U; Wannesson L; Leslie L; Kersten MJ; Jacobson CA; Pagel JM; Wulf G; Johnston P; Rapoport AP; Du L; Vardhanabhuti S; Filosto S; Shah J; Snider JT; Cheng P; To C; Oluwole OO; Sureda A
Clin Cancer Res; 2023 May; 29(10):1894-1905. PubMed ID: 36999993
[TBL] [Abstract][Full Text] [Related]
27. Lisocabtagene maraleucel for relapsed or refractory large B-cell non-Hodgkin lymphoma.
Mohty R; Moreno Vanegas Y; Chavez JC; Kharfan-Dabaja MA
Expert Rev Anticancer Ther; 2023 Feb; 23(2):121-126. PubMed ID: 36662602
[TBL] [Abstract][Full Text] [Related]
28. Matching-adjusted indirect comparison of axi-cel and liso-cel in relapsed or refractory large B-cell lymphoma.
Oluwole OO; Chen JMH; Chan K; Patel AR; Jansen JP; Keeping S; Zheng Y; Snider JT; Locke FL
Leuk Lymphoma; 2022 Dec; 63(13):3052-3062. PubMed ID: 36048026
[TBL] [Abstract][Full Text] [Related]
29. Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study.
Sehgal A; Hoda D; Riedell PA; Ghosh N; Hamadani M; Hildebrandt GC; Godwin JE; Reagan PM; Wagner-Johnston N; Essell J; Nath R; Solomon SR; Champion R; Licitra E; Fanning S; Gupta N; Dubowy R; D'Andrea A; Wang L; Ogasawara K; Thorpe J; Gordon LI
Lancet Oncol; 2022 Aug; 23(8):1066-1077. PubMed ID: 35839786
[TBL] [Abstract][Full Text] [Related]
30. A Model to Estimate Cytokine Release Syndrome and Neurological Event Management Costs Associated With CAR T-Cell Therapy.
Badaracco J; Gitlin M; Keating SJ
Transplant Cell Ther; 2023 Jan; 29(1):59.e1-59.e6. PubMed ID: 36272529
[TBL] [Abstract][Full Text] [Related]
31. Cost-Effectiveness of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel and Tisagenlecleucel in the Third-Line or Later Treatment Setting for Relapsed or Refractory Large B-cell Lymphoma in the United States.
Parker C; Liu FF; Deger KA; Franco-Villalobos C; Proskorovsky I; Keating SJ; Sorensen S
Adv Ther; 2023 May; 40(5):2355-2374. PubMed ID: 36947328
[TBL] [Abstract][Full Text] [Related]
32. Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001.
Abramson JS; Palomba ML; Gordon LI; Lunning M; Wang M; Arnason J; Purev E; Maloney DG; Andreadis C; Sehgal A; Solomon SR; Ghosh N; Dehner C; Kim Y; Ogasawara K; Kostic A; Siddiqi T
Blood; 2024 Feb; 143(5):404-416. PubMed ID: 37890149
[TBL] [Abstract][Full Text] [Related]
33. Value for Money of CAR-T Cell Therapy for Patients with Diffuse Large B-cell Lymphoma in China: Evidence from a Cost-Effectiveness Analysis.
Wu W; Zhou Y; Wang Y; Keramat SA; Balasooriya NN; Zhao Z; Yang Y; Comans T; Dong H
Appl Health Econ Health Policy; 2023 Sep; 21(5):773-783. PubMed ID: 37356080
[TBL] [Abstract][Full Text] [Related]
34. Lisocabtagene Maraleucel in Relapsed or Refractory Diffuse Large B Cell Lymphoma: What is the Evidence?
Kharfan-Dabaja MA; Yassine F; Moustafa MA; Iqbal M; Murthy H
Hematol Oncol Stem Cell Ther; 2022 Dec; 15(4):168-175. PubMed ID: 34699774
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness analysis 3L of axicabtagene ciloleucel vs tisagenlecleucel and lisocabtagene maraleucel in Japan.
Tsutsué S; Makita S; Asou H; Matsuda H; Yamaura R; Taylor TD
Future Oncol; 2024 Apr; ():1-17. PubMed ID: 38597742
[TBL] [Abstract][Full Text] [Related]
36. Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleucel versus tisagenlecleucel.
Cartron G; Fox CP; Liu FF; Kostic A; Hasskarl J; Li D; Bonner A; Zhang Y; Maloney DG; Kuruvilla J
Exp Hematol Oncol; 2022 Mar; 11(1):17. PubMed ID: 35337365
[TBL] [Abstract][Full Text] [Related]
37. Exploration of Tumor Biopsy Gene Signatures to Understand the Role of the Tumor Microenvironment in Outcomes to Lisocabtagene Maraleucel.
Olson NE; Ragan SP; Reiss DJ; Thorpe J; Kim Y; Abramson JS; McCoy C; Newhall KJ; Fox BA
Mol Cancer Ther; 2023 Mar; 22(3):406-418. PubMed ID: 36595660
[TBL] [Abstract][Full Text] [Related]
38. Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study.
Morschhauser F; Dahiya S; Palomba ML; Martin Garcia-Sancho A; Reguera Ortega JL; Kuruvilla J; Jäger U; Cartron G; Izutsu K; Dreyling M; Kahl B; Ghesquieres H; Ardeshna K; Goto H; Barbui AM; Abramson JS; Borchmann P; Fleury I; Mielke S; Skarbnik A; de Vos S; Kamdar M; Karmali R; Viardot A; Farazi T; Fasan O; Lymp J; Vedal M; Nishii R; Avilion A; Papuga J; Kumar J; Nastoupil LJ
Nat Med; 2024 Jun; ():. PubMed ID: 38830991
[TBL] [Abstract][Full Text] [Related]
39. Novel CAR T cell therapies for patients with large B cell lymphoma.
Goto H; Onozawa M; Teshima T
Int J Hematol; 2024 May; ():. PubMed ID: 38795249
[TBL] [Abstract][Full Text] [Related]
40. Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b-2, open-label study.
Martin T; Lin Y; Agha M; Cohen AD; Htut M; Stewart AK; Hari P; Berdeja JG; Usmani SZ; Yeh TM; Olyslager Y; Goldberg JD; Schecter JM; Madduri D; Jackson CC; Deraedt W; Gries KS; Fastenau JM; Trudeau JJ; Akram M; Pacaud L; Jakubowiak A; Jagannath S
Lancet Haematol; 2022 Dec; 9(12):e897-e905. PubMed ID: 36215989
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
